How is the half-life of monovalent nabodies compared to that of full monoclonal antibodies when used in vivo? Can that strategy be applied to Fab-s?

It is mi understanding that in the case of monoclonal antibodies the Fc domain enables higher half-life values in vivo. As the nanobodies are used without the Fc domain, how are they engineered to maintain half-lifes high enough to be used as therapeutic agents? And could that Read more Read less